Fig. 2.

Changes in PAI-1 plasma concentrations in Control and RESMENA groups from baseline to the endpoint of the intervention and differences between them (A); comparison between Control and RESMENA groups levels of SERPINE1 CpG 10 methylation (%) at baseline (B); comparison of PAI-1 plasma concentrations within Control and RESMENA groups according to SERPINE1 CpG 10 baseline methylation level (%) (C) and correlation analysis between methylation in the SERPINE1 CpG 10 and total fat mass by Dual-energy X-ray absorptiometry at baseline (D). PAI-1: plasminogen activator inhibitor 1.